Latest Non Dilutive Funding News

Critica Limited is progressing its Jupiter and Mt Lindsay projects with key resource updates, metallurgical breakthroughs, and strategic partnerships, targeting Scoping Study completion in Q3 2026.

Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.

Blackpearl Group has posted a record 114% jump in Annual Recurring Revenue to NZD 26.8 million, powered by its Pearl Engine vertical AI model that benchmarks 25 times better than leading generalist AI. Despite deepening losses, the firm targets balanced growth and cash conversion in FY27.

Redcastle Resources has launched continuous mining at its Redcastle Reef gold deposit, advancing from exploration to production under a capital-light joint venture with BML Ventures. Ore haulage to third-party processing is scheduled to begin in June 2026, with first toll treatment expected in July.

HIQ Limited has locked in non-dilutive funding from the Victorian Government to underpin a $4.9 million project expanding its manufacturing and research footprint in Victoria, supporting its global growth ambitions.

Ariana Resources has monetised part of its Zenit holding for US$19.5 million cash, retaining a 9.9% stake and boosting its war chest to advance the Dokwe Gold Project feasibility study in Zimbabwe.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Alicanto Minerals has struck strategic earn-in agreements for its Swedish projects potentially worth A$21 million, while expanding its Mt Henry Gold Project footprint in Western Australia and proposing a name change to Sinclair Gold.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Anson Resources' US arm, A1 Lithium, secures membership in a key US defense consortium, boosting government ties and funding prospects. Its Yellow Cat project earns a positive technical feasibility rating, aligning with US critical minerals priorities.

EMVision is broadening its emu™ Pivotal Trial to include acute ischaemia detection, aiming to accelerate FDA clearance and enhance the brain scanner's clinical impact. Recruitment has passed 125 patients across US and Australian sites, with full enrolment expected by early 2027.

Litchfield Minerals denies undisclosed material information behind recent share price jump, pointing to public engagement, media activity, and early-stage exploration sample processing as key influences.